Suppr超能文献

相似文献

4
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.
6
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.
10
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.

引用本文的文献

3
Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review.
Breast Cancer (Dove Med Press). 2025 Jun 30;17:557-565. doi: 10.2147/BCTT.S529794. eCollection 2025.
5
CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment.
Front Pharmacol. 2025 May 12;16:1549520. doi: 10.3389/fphar.2025.1549520. eCollection 2025.
7
Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer.
Front Oncol. 2025 Apr 30;15:1566146. doi: 10.3389/fonc.2025.1566146. eCollection 2025.
9
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment.
Oncogene. 2025 May;44(17):1135-1152. doi: 10.1038/s41388-025-03378-0. Epub 2025 Apr 8.
10
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials.
EClinicalMedicine. 2025 Jan 10;79:102987. doi: 10.1016/j.eclinm.2024.102987. eCollection 2025 Jan.

本文引用的文献

3
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication.
Ther Adv Med Oncol. 2019 May 10;11:1758835919833867. doi: 10.1177/1758835919833867. eCollection 2019.
4
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Cancer Sci. 2019 Apr;110(4):1420-1430. doi: 10.1111/cas.13957. Epub 2019 Feb 26.
5
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.
Cancer Treat Rev. 2019 Mar;74:21-28. doi: 10.1016/j.ctrv.2019.01.006. Epub 2019 Jan 19.
6
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.
10
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验